| 1.57 -0.09 (-5.42%) | 04-19 09:35 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.01 | 1-year : | 2.25 |
| Resists | First : | 1.72 | Second : | 1.92 |
| Pivot price | 1.62  |
|||
| Supports | First : | 1.39 | Second : | 1.16 |
| MAs | MA(5) : | 1.62 |
MA(20) : | 1.64 |
| MA(100) : | 1.32 |
MA(250) : | 1.62 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 25.9 |
D(3) : | 28.7 |
| RSI | RSI(14): 55.3 |
|||
| 52-week | High : | 2.31 | Low : | 0.91 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HCWB ] has closed below upper band by 32.0%. Bollinger Bands are 27% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.59 - 1.6 | 1.6 - 1.61 |
| Low: | 1.51 - 1.52 | 1.52 - 1.53 |
| Close: | 1.58 - 1.59 | 1.59 - 1.6 |
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Wed, 17 Apr 2024
Recent gains in HCW Biologics Inc. (NASDAQ:HCWB) help add back some value on insider purchases worth US$6.8m ... - Yahoo Movies Canada
Tue, 02 Apr 2024
HCW Biologics Inc. (NASDAQ:HCWB) Sees Large Drop in Short Interest - MarketBeat
Mon, 01 Apr 2024
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights - GlobeNewswire
Tue, 26 Mar 2024
HCWB Stock Quote Price and Forecast - CNN
Tue, 27 Feb 2024
Bullish HCW Biologics Insiders Loaded Up On US$2.92m Of Stock - Simply Wall St
Sat, 24 Feb 2024
Rebecca Byam Bought 122% More Shares In HCW Biologics - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 51.9 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 24 (K) |
| EPS | -0.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | -813.4 % |
| Return on Assets (ttm) | -42.7 % |
| Return on Equity (ttm) | -98.3 % |
| Qtrly Rev. Growth | -1.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.07 |
| EBITDA (p.s.) | -0.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -2.38 |
| PEG Ratio | 0 |
| Price to Book value | 4.48 |
| Price to Sales | 22.1 |
| Price to Cash Flow | -2.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|